Cargando…
Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer
BACKGROUND: The efficacy of adjuvant chemotherapy in patients with 8th edition stage IB (tumor size ≤4 cm) non-small cell lung cancer (NSCLC) remains unclear. METHODS: We identified 9757 eligible patients (non-chemotherapy group: n=8303; chemotherapy group: n=1454) between 2004 and 2016 from the Sur...
Autores principales: | Xu, Yangyang, Wan, Bing, Zhu, Suhua, Zhang, Tianli, Xie, Jingyuan, Liu, Hongbing, Zhan, Ping, Lv, Tangfeng, Song, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828472/ https://www.ncbi.nlm.nih.gov/pubmed/35155190 http://dx.doi.org/10.3389/fonc.2021.784289 |
Ejemplares similares
-
Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual
por: Wu, Lei-Lei, et al.
Publicado: (2020) -
Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB–IIA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2022) -
The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Xu, Yangyang, et al.
Publicado: (2021) -
Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022) -
Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)